Invion appoints experts to its Scientific Advisory Board

Company News

by Anna Napoli

Cancer therapy developer, Invion (ASX:IVX) has strengthened its scientific advisory board appointing experts in skin, lung and prostate cancer.

New appointees include, Dr Lynda Spelman, Assoicate Professor Louis Irving and Associate Professor Nathan Lawrentschuk.

Invion says the appointments will advance clinical development and help ensure that the Invion drugs and devices are optimized for each cancer type.

The company is developing photodynamic therapies for a range of cancers including skin, ovarian prostate and lung cancer.

Shares in Invion (ASX:IVX) last traded at 6 cents.

Anna Napoli

Finance News Network
Anna joined FNN February 2018 and also works with Channel 7 as a freelance producer. Anna has also worked as a lawyer and lecturer. She has also presented news updates for interstate news with Southern Cross Austereo.